Background: TR-700 is the active moiety of TR-701 (DA-7157), a new oral/intravenous oxazolidinone prodrug. We examined its activity against linezolid-susceptible and -resistant staphylococci and enterococci.
Introduction
Linezolid is the only oxazolidinone antibiotic currently approved and has been marketed for around 8 years. It retains near-universal activity against Gram-positive cocci, with resistance rates below 1% in most surveillance studies. Nevertheless, its modal MICs for staphylococci and enterococci are only one doubling dilution below CLSI and EUCAST breakpoints of 2-4 mg/L, and resistant mutants are occasionally selected in therapy. 1 Their relative rarity may partly reflect the fact that, owing to toxicity concerns, most linezolid therapy is now of brief duration, whereas the selection risk increases with prolonged exposure. On a few occasions, linezolid-resistant strains have caused outbreaks 2 and have spread between hospitals (HPA, data on file).
The most common mechanism of linezolid resistance entails mutations of the 23S rRNA, most often G2576U (G2576T in the corresponding DNA), which alter the compound's binding site. 3 Clinically relevant Gram-positive cocci have four to seven 23S rRNA gene copies, and two or more copies must be altered for resistance, which therefore arises only if an initial mutation is followed by internal recombinations. 3, 4 MICs are highest, at up to 64 mg/L, for mutants homozygous for T2576 in their 23S rRNA genes. 3, 4 Plasmid-mediated resistance, determined by the Cfr rRNA methylase, was first described in a porcine isolate 5 and, more recently, has been found in several linezolid-resistant clinical strains of Staphylococcus aureus and Staphylococcus epidermidis from humans. 6 We compared the MICs of TR-700 ( Figure 1a ) (DA-7157; Trius Therapeutics, Inc., San Diego, CA, USA) with those of linezolid (Figure 1b) . TR-700 is the active moiety of a novel oxazolidinone phosphate ester prodrug, TR-701 (DA-7218), 7, 8 and is rapidly generated during the absorption process, and in blood following oral or intravenous administration of TR-701 (Figure 1a) . 7 Recent clinical studies have shown that TR-701 is undetectable in plasma after oral administration of doses from 200 to 400 mg once daily. 9 
Materials and methods
The organisms tested were clinical isolates of methicillin-resistant S. aureus (MRSA) or enterococci, categorized as linezolidsusceptible or -resistant based on previous testing by the BSAC agar dilution method. Most were from the UK, though a few resistant organisms from Austria were also included. Previous investigation had shown that virtually all of the resistant isolates tested had G2576T, and the numbers of native and mutated 23S rRNA gene copies were estimated by pyrosequencing. 3 In addition, we tested a few laboratory mutants of MRSA, with different mutations leading to linezolid resistance. . .. .. .. .. .. .. . .. .. .. .. .. .. .. . .. .. .. .. .. .. .. .. . .. .. .. .. .. .. .. .. . .. .. .. .. .. .. .. .. . .. .. .. .. .. .. .. .. . .. .. .. .. .. .. .. .. . .. .. .. .. .. .. .. . .. .. .. .. .. .. .. .. . .. .. .. .. .. .. . . .. .
MICs were determined by the CLSI agar dilution method on Mueller -Hinton agar (Oxoid/Thermofisher, Basingstoke, UK).
Results and discussion
MIC distributions are shown in Table 1 . In general, TR-700 was 4-fold more active than linezolid against linezolid-susceptible clinical staphylococci and enterococci, with its MICs tightly clustered around 0.5 mg/L compared with 2 mg/L for linezolid. A model of the binding of TR-700 to the peptidyltransferase region of the ribosome suggests that the increased potency compared with linezolid is due to two additional target site hydrogen bond interactions between TR-700 and the ribose sugars of A2451 and U2584. 8 As with linezolid, the MICs for enterococci were independent of species and vancomycin resistance. MICs for linezolidresistant organisms were higher and more scattered, but substantially lower than for linezolid. Thus MICs of TR-700 remained in the 1 -4 mg/L range versus 8-64 mg/L for linezolid against 10 linezolid-resistant MRSA and 6 coagulase-negative staphylococci. Among enterococci, only 3/36 linezolid-resistant (i.e. MIC .4 mg/L) organisms were resistant also to TR-700 at 4 mg/L. Two of three, with TR-700 MICs of 8 mg/L, were Enterococcus faecium isolates homozygous for T2576 while the remaining one, with an MIC of 16 mg/L, was an E. faecium that lacked any 23S rRNA lesion and was also negative, by PCR, for the cfr gene. MICs of TR-700 were 1-2 mg/L, compared with 8 -32 mg/L linezolid for seven laboratory-derived S. aureus mutants (not included in the tables) with various linezolidcompromising mutations (G2447T, G2576T and G2766T together with A2503G); these values compared with MICs of 0.25 -0.5 mg/L for TR-700 and 2 mg/L for linezolid for the two parent strains.
Among isolates confirmed by sequencing to have G2576T mutations, there was a positive correlation between the number of gene copies altered and the MICs of both linezolid and TR-700 (Table 2) .
In summary, TR-700 was 4-fold more active than linezolid versus linezolid-susceptible staphylococci and enterococci, with tightly clustered MICs. Against linezolid-resistant strains, the MIC differential in favour of TR-700 was often 8-fold, with only a small minority of the linezolid-resistant isolates-principally those homozygous for T2576-resistant at 4 mg/L. Assuming breakpoints similar to linezolid, TR-700 should offer an advantage, overcoming most linezolid resistance, and may also be less likely to select for resistance. Alternatively, a lower dose might be used, reducing the potential for toxicity. In either case, the therapeutic window is potentially wider than for linezolid. Human Phase 1 multiple-dose steady-state PK data suggest a linear relationship between C max (1.8 -4.5 mg/L) and dosage (200, 300 and 400 mg), with a t 1/2 of 8.4 -10.2 h, allowing once-daily administration. 9 
